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Abstract: Emodin is a multifunctional Chinese traditional medicine with poor water solubility. 
D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) is a pegylated vitamin E derivate. 
In this study, a novel liposomal-emodin-conjugating TPGS was formulated and compared 
with methoxypolyethyleneglycol 2000-derivatized distearoyl-phosphatidylethanolamine 
(mPEG2000–DSPE) liposomal emodin. TPGS improved the encapsulation efficiency and stabil-
ity of emodin egg phosphatidylcholine/cholesterol liposomes. A high encapsulation efficiency of 
95.2% ± 3.0%, particle size of 121.1 ± 44.9 nm, spherical ultrastructure, and sustained in vitro 
release of TPGS liposomal emodin were observed; these were similar to mPEG2000–DSPE 
liposomes. Only the zeta potential of –13.1 ± 2.7 mV was significantly different to that for 
mPEG2000–DSPE liposomes. Compared to mPEG2000–DSPE liposomes, TPGS liposomes 
improved the cytotoxicity of emodin on leukemia cells by regulating the protein levels of 
myeloid cell leukemia 1 (Mcl-1), B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein, 
which was further enhanced by transferrin. TPGS liposomes prolonged the circulation time of 
emodin in the blood, with the area under the concentration–time curve (AUC) 1.7 times larger 
than for free emodin and 0.91 times larger than for mPEG2000–DSPE liposomes. In addition, 
TPGS liposomes showed higher AUC for emodin in the lung and kidney than for mPEG2000–
DSPE liposomes, and both liposomes elevated the amount of emodin in the heart. Overall, 
TPGS is a pegylated agent that could potentially be used to compose a stable liposomal emodin 
with enhanced therapeutics.
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Introduction
Emodin is an active anthraquinone from the root and rhizome of Chinese herbs such 
as Rheum palmatum Linnaeus and Polygonum cuspidatum Sieb. et Zucc. (Figure 1). 
Emodin shows a wide variety of pharmacological activities such as anticancer,1–4 anti-
fibrosis,5–7 antirestenosis,8,9 and antimicrobial activities.10 However, emodin is poorly 
soluble in water, which limits its applications in vivo.
In a previous publication, emodin exhibited a high affinity for phospholipids such 
as 1,2-dimiristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristoyl-sn-glycero-
3-[phospho-rac-(1-glycerol)], and 1,2-dielaidoyl-sn-glycero-3-phosphoethanolamine, 
and emodin in such preparations exhibited stronger antibacterial activity than free 
emodin.10 In addition, silk-fibroin-coated DMPC/Tween20 liposomal emodin was 
much more effective on breast cancer cells than nontargeted liposomal emodin.11,12 
However, there were no further in vivo studies reported until now.
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Liposomal stability and circulation time in the blood are 
critical for the targeting delivery system, which is strongly 
influenced by the hydrophilic stealth layer, zeta potential, 
lipid compositions, particle size and distribution, etc. 
Methoxypolyethyleneglycol 2000-derivatized distearoyl-
phosphatidylethanolamine (mPEG2000–DSPE) is a widely 
used stealth modifier in liposomal formulations to provide 
nanocarriers with a long circulation time and specific 
  stability. Because mPEG2000–DSPE has a  polyethylene 
glycol (PEG) molecular weight of 2000, it not only prevents 
the contact of liposomes with the targeted cells but also 
results in side effects such as skin toxicity from its extended 
circulation time.13 Vitamin E is widely used as an antioxi-
dant agent in liposome formulations or emulsions to avoid 
phospholipid oxidation. D-α-tocopheryl polyethylene glycol 
1000 succinate (TPGS) is a water-soluble vitamin E derivate, 
with a shorter PEG chain than that of mPEG2000–DSPE. 
Furthermore, TPGS has been demonstrated to achieve a 
smaller micellar particle size (by reducing the surface ten-
sion of lipid   membranes) and enhance the micellar stabil-
ity of poly(ethylene glycol)-phosphatidyl ethanolamine 
(PEG-PE).14,15 Therefore, we hypothesize that TPGS is a 
potential pegylated alternative to improve the physical stabil-
ity of liposomes and formulate a liposomal emodin to provide 
an appropriate circulation time in the blood.
Transferrin receptor (TfR) is a dimeric transmembrane 
glycoprotein (180 kDa) frequently upregulated in a   majority 
of tumor cells, such as K562 and MV4-11 leukemia cells.16,17 
Transferrin (Tf), the ligand for TfR, is an 80 kDa iron-
transporting glycoprotein that can be taken up by cells via 
TfR-mediated endocytosis.18 Tf-conjugated polymers or 
liposomes have been studied previously for delivering both 
oligonucleotides and chemotherapeutic agents to achieve 
selective targeting of tumor cells.19
Based on the above, a novel liposomal emodin formu-
lation containing TPGS has been developed in this study. 
Encapsulation efficiency (EE), particle size, zeta potential, 
morphology, in vitro release, pharmacokinetics and biodis-
tributions, in vitro cytotoxicity, and mechanisms of TPGS 
liposomal emodin with or without Tf on leukemia cells 
have been thoroughly compared with mPEG2000–DSPE 
liposomal emodin.
Methods and materials
Materials
Emodin (99% purity) was purchased from Shanxi Sciphar 
Biotechnology Co, Ltd (Xi’an, China). Egg phosphatidylcholine 
(EPC), hydrogenated soy phosphatidylcholine (HSPC), 
cholesterol (Chol), distearoylphosphatidylethanolamine-
N-maleimide polyethylene glycol 3350 (MAL–PEG3350–
DSPE), and mPEG2000–DSPE were purchased from Avanti 
Polar Lipids Inc (Alabaster, AL). Human holotransferrin, 
2-iminothiolane (Traut’s reagent), and 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyltetrazolium bromide (MTT) were 
purchased from Sigma Chemical Co (St Louis, MO). TPGS 
was provided by Eastman Chemical Company (Kingsport, 
TN). The LiposoFast-Basic™ Extruder was purchased from 
Avestin (Ottawa, ON) and the polycarbonate membrane from 
Whatman (Maidstone, UK).
Liposome preparation
Emodin liposomes were prepared by thin-film hydration, 
polycarbonate membrane extrusion. The formulation 
c  ompositions of transferrin-targeted emodin liposomes and 
nontargeted emodin liposomes are shown in Table 1.   Lipids 
and emodin were dissolved in a mixture of chloroform 
(CHCl3): methonal (V/V , 9/1). The solvents were removed by 
reduced-pressure evaporation at 40°C. The formed thin film 
was hydrated with saline. Extrusion through various sized 
pore polycarbonate membranes was carried out five times 
to generate small unilamellar vesicles (SUV).
A postinsertion method was adopted to incorporate the 
Tf ligand onto the emodin liposomes. Holo-Tf (diferric 
Tf) was reacted with 5× Traut’s reagent to yield holo-Tf-
SH. Free sulfhydryl content in holo-Tf-SH was measured 
by   Ellman’s reagent. The holo-Tf-SH was then reacted to 
micelles of MAL–PEG3350–DSPE at a molar ratio of 1:10 
and then incubated with liposomal emodin for 1 hour at 
37°C. Targeted liposomes with transferrin polyethylene 
  glycol 3350-derivatized distearoyl-phosphatidylethanolamine 
(Tf–PEG3350–DSPE) to lipids at a molar ratio of 1:200 
were prepared. Nontargeted liposomes for studies on cells 
were prepared by coupling bovine serum albumin instead of 
Tf to the liposomes, utilizing the same method.
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O
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Figure 1 Chemical structure of emodin.
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Characteristics of liposomes
Free emodin and liposomal emodin were separated by size 
exclusion chromatography on a Sepharose CL-4B column 
(Sigma-Aldrich, St Louis, MO). Liposomal emodin and the 
nonseparation emodin liposomes were lysed by 1.0% Triton 
X-100 and emodin was determined by high-performance 
liquid chromatography (HPLC), respectively. The EE was 
calculated according to the formula:
EE
W
W
liposomal ei n
nonseparatione in liposomes
=×
−
−−
mod
mod
100%.
The mean diameter and distribution of liposomes were 
determined by dynamic light scattering using a NICOMP 
Model 370 Submicron Particle Sizer (Particle Sizing 
    Systems, Santa Barbara, CA).
The zeta potential of liposomes was measured by Zeta 
PALS (Zeta Potential Analyzer, Brookhaven Instruments 
Corporation, NY).
The ultrastructure of the emodin liposomes was inves-
tigated by transmission electron micrography (JEM-1400; 
JEOL, Tokyo Japan) after negative staining with sodium 
phosphotungstate solution (2% w/v).
In vitro release
Comparisons of emodin released in vitro from liposomes 
conjugating TPGS or mPEG2000–DSPE were conducted by 
dialysis. 0.2 mL of liposomal emodin with an equal volume 
of media was placed in a dialysis tube (molecular weight 
cut-off 12,000–14,000; Spectrum Laboratories, Inc, Rancho 
Dominguez, CA) and then suspended in 50 mL of citrate 
buffer (pH 5.0) or phosphate-buffered saline (PBS; pH 7.4) 
at 37°C. To investigate the influence of serum albumin on 
the in vitro release, 0.2 mL of liposomal emodin was mixed 
with an equal volume of human plasma, placed in the dialy-
sis tube, and then suspended in 50 mL of PBS (pH 7.4). At 
predetermined time intervals, aliquots were withdrawn and 
emodin was assayed by HPLC.
Cell culture
L1210 and K562 cells were cultured in an RPMI 1640 media 
(Life Technologies, Inc, Bethesda, MD), MV4-11 cells were 
cultured in DMEM media (Life Technologies, Inc), supple-
mented with 50 µg/mL penicillin, 50 µg/mL streptomycin, 
and 10% fetal bovine serum. Cells were maintained in a 
humidified atmosphere containing 5% CO2 at 37°C.
In vitro cytotoxicity
Cytotoxicity of liposomal emodin formulations on leukemia 
cell lines was determined using MTT. Briefly, cells were 
harvested during the logarithmic growth phase and seeded in 
96-well plates at a final density of 2–4 × 103 per well. After 
24 hours of incubation, the culture medium was replaced by 
200 µL of fresh media containing serial dilutions of emo-
din formulations. Following 72 hours of treatment at 37°C 
in the incubator, 20 µL of MTT solution (5 mg/mL) was 
added to each well, and the plates were incubated for another 
4 hours. Then the medium was removed after c  entrifugation 
Table 1 Encapsulation efficiency and particle size of emodin liposomes based on various formulation compositions and manufacturing 
processes
No Formulation (molar ratio) Process EE (%) Particle size (nm)
1 EPC/Chol/TPgS (95/0/5) Ultrasound 78.2 ± 2.0   37.5 ± 22.1
2 EPC/Chol/TPgS (75/20/5) Ultrasound 82.7 ± 1.1   40.4 ± 23.0
3 EPC/Chol/TPgS (55/40/5) Ultrasound 85.8 ± 1.3   49.4 ± 25.6
4 EPC/Chol/TPgS (40/55/5) Ultrasound 84.4 ± 1.4   61.0 ± 41.8
5 EPC/Chol/TPgS (50/40/10) Ultrasound 84.5 ± 2.1   44.6 ± 23.4
6 EPC/Chol/TPgS (46/30/23) Ultrasound 84.6 ± 1.8   33.1 ± 21.5
7 EPC/Chol/mPEg2000–DSPE (55/40/5) Ultrasound 86.8 ± 2.3   48.2 ± 24.5
8 EPC/Chol/TPgS (55/40/5) Extrusion (50 nm) 92.8 ± 0.7   48.5 ± 24.3
9 EPC/Chol/TPgS (55/40/5) Extrusion (100 nm) 95.6 ± 1.0   91.8 ± 42.4
10 EPC/Chol/TPgS (55/40/5) Extrusion (200 nm) 96.5 ± 0.9 125.8 ± 55.1
11 EPC/Chol/TPgS/Tf–PEg3350–DSPE (55/40/4.5/0.5) Extrusion (50 nm) 93.5 ± 0.9   49.0 ± 25.1
12 EPC/Chol/TPgS/Tf–PEg3350–DSPE (55/40/4.5/0.5) Extrusion (100 nm) 95.4 ± 0.9   94.6 ± 41.8
13 EPC/Chol/TPgS/Tf–PEg3350–DSPE (55/40/4.5/0.5) Extrusion (200 nm) 96.2 ± 0.6 120.1 ± 55.6
Notes: Numbers 1–10 refer to nontargeted emodin liposomes. 11–13 refer to transferrin-targeted emodin liposomes.
Abbreviations: EE, encapsulation efficiency; EPC, egg phosphatidylcholine; Chol, cholesterol; TPGS, D-α-tocopheryl polyethylene glycol 1000 succinate; nm, nanometer; 
mPEg2000–DSPE, methoxypolyethyleneglycol 2000-derivatized distearoyl-phosphatidylethanolamine; Tf–PEg3350–DSPE, transferrin polyethyleneglycol 3350-derivatized 
distearoyl-phosphatidylethanolamine.
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at 2000 rpm for 10 minutes. 200 µL of dimethyl sulfoxide 
(DMSO) was added to each well to dissolve the blue for-
mazan crystal converting from the MTT. Cell viability was 
assessed by absorbance at 570 nm on a microplate reader 
(Bio-Rad Laboratories, Richmond, CA), and the half maxi-
mal inhibitory concentration (IC50) was used to measure the 
effectiveness of various formulations.
Western blot analysis
Western blotting was used to determine the protein level of 
B-cell lymphoma-2 (Bcl-2), myeloid cell leukemia 1 (Mcl-1), 
and Bcl-2-associated X protein (Bax) in the K562 and MV 
4-11 cells after treatment using emodin formulations for 
72 hours. Briefly, cells were seeded in 12-well plates at a 
final density of 2–4 × 103 per well. After 24 hours of incuba-
tion, the culture medium was replaced by 1000 µL of fresh 
media containing serial dilutions of emodin formulations. 
After 72 hours of treatment in the incubator, the cells were 
washed three times with cold PBS, harvested and lysed using 
a 1× cell lysis buffer containing a protease inhibitor cocktail 
(CalBiochem, San Diego, CA). Then, the supernatants were 
collected after centrifugation at 12,000 g for 15 minutes at 
4°C. The protein concentrations in the supernatants were 
determined using bicinchoninic acid. Approximately 20 µg 
of cellular protein was loaded and separated using 12.5% 
sodium dodecyl sulfate polyacrylamide gel electrophoresis. 
After that, the proteins were transferred electrophoretically 
onto nitrocellulose membranes (0.2 mm; Schleicher and 
Schuell, Keene, NH). The membranes were then blocked 
with 5% nonfat dried milk in Tris-buffered saline and subse-
quently probed with a primary antibody, such as polyclonal 
rabbit anti-human Bcl-2, polyclonal rabbit anti-human 
Mcl-1, polyclonal rabbit anti-human Bax, and polyclonal 
goat anti-human β-actin (Santa Cruz Biotech, Santa Cruz, 
CA) in Tris-buffered saline containing 3% nonfat dried milk, 
respectively. Antibody-antigen complexes were detected 
using goat anti-rabbit immunoglobulin G–horseradish 
peroxidase-conjugated antibodies and an enhanced chemilu-
minescence detection kit (Amersham Pharmacia Biotech, San 
Francisco, CA). Bcl-2, Mcl-1, and Bax protein expression 
levels were quantified by using ImageJ software (National 
Institutes of Health, Bethesda, MD) and were normalized to 
the β-actin levels.
In vivo animal study
Animals
Imprinting Control Region mice weighing 20–22 g were 
purchased from Shanghai Slac Laboratory Animal Co, Ltd 
(Shanghai, People’s Republic of China). All mice were fed 
and maintained under constant conditions at temperature of 
20°C–25°C, humidity 55% ± 5%, with cycles of 12 hours of 
light and 12 hours of dark. Water and food were accessible 
to mice ad libitum. All animal experiments were performed 
according to international ethical standards, and the protocol 
was approved by the Institutional Animal Ethics Committee 
of Zhejiang University of Technology (Zhejiang, People’s 
Republic of China).
Pharmacokinetics and biodistribution
Imprinting control region mice (age 6–8 weeks, half male 
and half female) were randomly divided into three groups 
of 30 each for TPGS liposomal emodin, mPEG2000–DSPE 
liposomal emodin, and free emodin solution. A single dose 
of emodin at 5 mg/kg was intravenously injected into each 
mouse. At 5, 15, 30, 60, 120, and 240 minutes after the drug 
administration, animals (five per time for each group) were 
sacrificed. Blood was taken from the orbital sinus and col-
lected in tubes with heparin, and plasma was obtained by 
centrifugation at 3500 rpm for 5 minutes. Tissues, such as 
heart, lung, liver, spleen, and kidney, were extracted, washed 
with cold saline, blotted with filter paper, and weighed. Both 
plasma and tissues were stored at −20°C until assay.
Biosample preparation
Weighed tissue samples were homogenized in saline to get 
a tissue concentration of 0.25 g/mL. First, 200 µL plasma 
or tissue homogenates were put in 1.5 mL Eppendorf tubes. 
Then, 40 µL NaOH (2.5 mol/L) and 1 mL ethyl acetate 
were added and vigorously mixed for 2 minutes. After that, 
60 µL of HCl (3 mol/L) was added and vigorously mixed 
for 1.5 minutes to neutralize the NaOH. The mixture was 
centrifuged at 10,000 rpm for 6 minutes. The supernatant of 
0.8 mL was transferred to a fresh 1.5 mL Eppendorf tube and 
dried by an air stream at 70°C. The residues were reconsti-
tuted in 100 µL of methanol and centrifuged at 10,000 rpm 
for 10 minutes before determination. A sample (15 µL) was 
injected into HPLC.
Determination of emodin
Emodin levels were determined by a HPLC-ultraviolet 
method (LC-10 ADT pump, SPD-10 A UV-VIS   detector; 
Shimadazu, Kyoto, Japan) utilizing a 4.6 × 250 mm ODS 
column (5 µm; Elite, Dalian, People’s Republic of China), 
preceded by a 5 mm guard column packed with ODS at 
column temperature of 30°C and wavelength of 290 nm. 
The mobile phase was a mixture of 0.2% acetic acid 
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s olution (pH 3.0) and methanol (20:80) at a flow rate of 
0.8 mL/minute. The chromatographic data were analyzed 
using N2000 software (Zhejiang University, Zhejiang, 
People’s Republic of China).
Statistical analysis
Data were reported as the mean ± standard deviation. 
  Statistical significance was measured by Student’s t-test and 
defined by P , 0.05.
Results and discussion
Formulation of liposomes
Emodin is a poorly water-soluble anthraquinone drug. Thin-
film-hydration was used to prepare emodin liposomes. In 
this study, the influences of formulation composition and 
manufacturing process on the emodin liposomes have been 
investigated.
EE and particle size of emodin liposomes based on vari-
ous lipids, pegylated agents, targeting anchor, ultrasound, 
and extrusion are summarized in Table 1. When the molar 
ratio of pegylated agent was zero, emodin was inclined to 
leak out from liposomes and recrystallize after overnight 
storage at 4°C (data not shown in Table 1). Interestingly, 
the particle size of emodin EPC/Chol/TPGS liposomes, 
prepared by ultrasound at 7 W for 30 seconds, decreased 
from 49.4 ± 25.6 nm to 33.1 ± 21.5 nm with the molar ratio 
of TPGS increasing from 5% to 23%, while the EE was not 
significantly influenced (P . 0.05). TPGS is a hydrophilic 
derivative of vitamin E-conjugated PEG 1000, with a hydro-
philic–lipophilic balance of 13 and a critical micelle concen-
tration of 26 µmol/L. Concentrations of TPGS in the EPC/
Chol liposomes were above its critical micelle   concentration. 
From these results, a higher ratio of TPGS resulted in smaller 
liposome particle size without significantly changing the EE; 
we can deduce that emodin was encapsulated in phospholipid 
liposomes, while not in TPGS micelles. On the other hand, 
TPGS may work as a pegylated agent by inserting a hydro-
phobic chain of vitamin E into the phospholipid bilayers and 
spreading out a PEG 1000 chain in the water phase to obtain 
the stable emodin liposomes.
The influences of EPC/Chol ratio on the EE and particle 
size at 5% (mol) TPGS were also investigated. With the molar 
ratio of cholesterol increasing from 0% to 55%, the particle 
size increased from 37.5 ± 22.1 nm to 61.0 ± 41.8 nm, while 
the highest EE (85.8% ± 1.3%) was obtained in the EPC/Chol 
(55/40) (P , 0.03). These suggest that suitable amount of 
cholesterol could also stabilize the phospholipid bilayers and 
elevate the entrapment of emodin in the TPGS liposomes.
Ultrasound reduces the liposome particle size by vigor-
ously ultrasonic cavitation, which may result in the partial 
leakage of the drug from the liposomes. In this work, extru-
sion through polycarbonate membrane using nitrogen was 
also studied. In comparison with the ultrasound method 
(EE 85.8% ± 1.3% and particle size 49.4 ± 25.6 nm), sig-
nificantly higher EE (92.8% ± 0.7%) and similar particle 
size (48.5 ± 24.3 nm of EPC/Chol/TPGS 55/40/5) were 
achieved by extrusion five times through pore size 50 nm 
polycarbonate membrane (P , 0.002). In addition, with 
a pore size increase from 50 nm to 200 nm, particle sizes 
increased from 48.5 ± 24.3 nm to 125.8 ± 55.1 nm and the 
emodin entrapments were also improved from 92.8% ± 0.7% 
to 97.5% ± 0.9% (P , 0.02). These data indicate that extru-
sion could avoid the ultrasonic leakage of liposomes and 
result in much higher encapsulation of emodin.
Further comparisons of TPGS and mPEG2000–DSPE on 
the emodin liposomes were carried out by either ultrasound 
or extrusion. At the same lipid molar ratio of 55/40/5, both 
EPC/Chol/TPGS and EPC/Chol/mPEG2000–DSPE lipo-
somes showed a similar EE and a similar particle size using 
both ultrasound (Table 1) and extrusion (Table 2). These data 
show that TPGS may be a potentially alternative pegylated 
agent to mPEG2000–DSPE.
Tf-tailored targeted emodin liposomes were composed by 
postinserting Tf–PEG3350–DSPE micelles into EPC/Chol/
TPGS emodin liposomes. Results indicated that insertion of 
Tf–PEG3350–DSPE did not significantly affect the EE and 
particle size (P . 0.19) (Table 1).
It has been reported that emodin has a high affinity for 
phospholipids such as DMPC, 1,2-dimyristoyl-sn-glycero-3-
[phospho-rac-(1-glycerol)], and 1,2-dielaidoyl-sn-glycero-3- 
phosphoethanolamine.10 This study also investigated HSPC 
as a phospholipid to compose emodin liposomes. It is surpris-
ing that similar entrapment of HSPC liposomes was obtained 
compared to EPC liposomes, while most of the emodin leaked 
out from the HSPC bilayers after several hours of storage. 
A possible reason is that emodin is an anthraquinone drug 
Table 2 Properties of emodin liposomes from extrusion
Formulations EE (%) Particle  
size (nm)
Zeta potential   
(mV)
TPgS liposomal  
emodin
95.2 ± 3.0 121.1 ± 49.2 −13.1 ± 2.7
mPEg2000–DSPE  
liposomal emodin
94.2 ± 1.8 121.7 ± 44.9 −41.7 ± 0.9
Abbreviations:  EE,  encapsulation  efficiency;  nm,  nanometer;  mV,  millivolt; 
EPC,  egg  phosphatidylcholine;  TPgS,  D-α-tocopheryl  polyethylene  glycol  1000 
succinate; mPEg2000–DSPE, methoxypolyethyleneglycol 2000-derivatized distearoyl- 
phosphatidylethanolamine.
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with poor water solubility which was incorporated in the 
phospholipid bilayers to form liposomes. EPC is a nonsatu-
rated phospholipid with a lower crystallization temperature 
than HSPC. Thus, emodin could move freely in the EPC 
bilayers, and the molecular interactions of emodin with EPC 
could reform quickly when the biomembranes crystallized. 
On the other hand, HSPC liposomes have solid structures, 
which forced emodin out of the HSPC bilayers during the 
microphase transformation. The above data suggest that 
EPC composed of TPGS or mPEG2000–DSPE is a potential 
carrier for emodin.
Characteristics of liposomes
The EPC/Chol/TPGS and EPC/Chol/mPEG2000–DSPE lipo-
somes (55/40/5 molar ratio) for loading emodin were prepared 
by thin-film-hydration-extrusion at an emodin-to-lipids weight 
ratio of 1/20 and an emodin concentration of 0.5 mg/mL. 
The properties of both liposomes have been compared. Data 
indicated that there were no significant differences for EE and 
particle size (P . 0.32) (Table 2). Due to the negative charge 
from mPEG2000–DSPE, the absolute zeta potential of the 
mPEG2000–DSPE liposomes (41.7 ± 0.9 mV) was higher 
than that of the TPGS liposomes (13.1 ± 2.7 mV).
The unilamellar vesicles with bright circles surrounding 
dark chambers can be seen in the liposomes on the upper 
layer, as shown in Figure 2. Due to the low crystallization 
temperature of EPC, some liposomes exhibited flowability, 
contacted each other and distorted. No significant differences 
between TPGS liposomal emodin and mPEG2000–DSPE 
liposomal emodin can be observed. Interestingly, the EE, par-
ticle size, and micromorphology of both liposomes remained 
similar even after storage for 2 years at 4°C, which further 
indicates that TPGS could form a steric layer around the EPC 
liposomes to stabilize the liposomal emodin.
In vitro release
To mimic the in vivo properties of liposomes, the in vitro 
release of TPGS and mPEG2000–DSPE liposomal emodin 
in PBS (pH 7.4), plasma, and citrate buffer (pH 5.0) by 
dialysis were compared. The release profiles of TPGS lipo-
somal emodin were similar to mPEG2000–DSPE liposomal 
emodin in three media (Figure 3). In the PBS (pH 7.4), both 
emodin liposomes released about 22% of the emodin in the 
first 24 hours, but from then until 72 hours, only 6% of the 
emodin was gradually released (Figure 3A). Of note, plasma 
mixed with emodin liposomes in the dialysis bag inhibited 
emodin releasing into the PBS (pH 7.4) and resulted in only 
16% of the emodin being released over 72 hours, as shown in 
Figure 3B. It has been reported that emodin has a high protein 
binding efficiency of 99.6%.20 When the mixtures of emodin 
liposomes (EE 78.8%) and plasma (1/4, V/V) were incubated 
at 37°C for 2 hours, the EE was raised about 5% for both 
TPGS and mPEG2000–DSPE liposomes. Thus, we deduce 
that the released emodin may conjugate with the plasma 
protein and cannot pass through the dialysis tube. To mimic 
the release ability of emodin liposomes from endosomes 
Figure  2  Transmission  electron  microscope  pictures  of  emodin  liposomes  by 
negative  staining  with  sodium  phosphotungstate  solution  (×20,000).  (A)  TPgS 
liposomal emodin; (B) mPEg2000–DSPE liposomal emodin.
Abbreviations:  TPgS,  D-α-tocopheryl  polyethylene  glycol  1000  succinate; 
mPEg2000–DSPE,  methoxypolyethyleneglycol  2000-derivatized  distearoyl-
phosphatidylethanolamine.
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Figure 3 In vitro release profiles of emodin liposomes by dialysis against three media. (A) emodin liposomes against PBS (pH 7.4); (B) emodin liposomes plus equal volume 
of plasma against PBS (pH 7.4); (C) emodin liposomes against citrate buffer (pH 5.0).
Notes: (▲: mPEg2000–DSPE liposomal emodin; ♦: TPgS liposomal emodin); error bars refer to standard deviations, n = 3.
Abbreviations: PBS, phosphate-buffered saline; TPgS, D-α-tocopheryl polyethylene glycol 1000 succinate; mPEg2000–DSPE, methoxypolyethyleneglycol 2000-derivatized 
distearoyl-phosphatidylethanolamine.
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with pH 5.0–6.5, in vitro release in the citrate buffer (pH 5.0) 
was carried out. Figure 3C showed that the smallest amount 
of emodin was released from the liposomes (about 5%). A 
possible reason is that there are three phenolic hydroxyls in 
emodin’s molecular structure, which give it lower   solubility 
in an acidic buffer. Although the in vitro release methods 
demonstrate this deficiency to some degree in this work, 
the above results suggest that TPGS does not affect the in 
vitro release of emodin from liposomes in comparison with 
mPEG2000–DSPE.
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Cell viability
Emodin exerts specifically antiproliferative effects to many 
cancer cells such as leukemia,1,21 breast cancer,12 lung can-
cer,2,22 and human hepatocellular carcinoma4 in vitro. To 
investigate whether TPGS liposomes enhance the cytotoxicity 
of emodin, the cell viability of leukemia cells was tested.
Cytotoxicity of TPGS liposomal emodin, mPEG2000–
DSPE liposomal emodin, and free emodin on L1210 leukemia 
cells showed that when L1210 cells are exposed to low con-
centrations of emodin, there was no difference to cell viability 
among various formulations. At concentrations higher than 
10 µmol/L, TPGS liposomal emodin presented a stronger 
inhibition to L1210 cells than mPEG2000–DSPE liposomal 
emodin and free emodin. The IC50 indicated that TPGS-
tailored liposomes enhanced the cytotoxicity of emodin, 
with an IC50 value only 0.21 times that of free emodin, while 
mPEG2000–DSPE liposomes diminished the cytotoxicity 
of emodin to a certain degree (Table 3). In addition, empty 
TPGS liposomes showed a similar IC50 (72 µmol/L) to free 
emodin (63 µmol/L). However, it is of note that at the IC50 of 
TPGS liposomal emodin (13.2 µmol/L), the concentration of 
TPGS is 17.2 µmol/L, while the cell viability of empty TPGS 
liposomes at TPGS 17.2 µmol/L is 85.4% ± 6.2%. Thus, the 
enhanced cytotoxicity of emodin is not simply the additive 
result of the free emodin and empty TPGS liposomes.
The transferrin receptor is overexpressed on leukemia 
cells such as K562 and MV4-11, and it has been evalu-
ated and used in transferrin-mediated targeting delivery 
to leukemia cells.16,17 To further study the antileukemia 
efficacy of TPGS liposomal emodin, Tf-targeted vesicles 
were composed by postinserting Tf–PEG3350–DSPE. The 
cytotoxicity of various emodin formulations on K562 and 
MV4-11 cells was compared. Data showed that TPGS lipo-
somes also enhanced the cytotoxicity of emodin to K562 
and MV 4-11 cells in comparison with free emodin, with 
IC50 31.2 µmol/L and 20.5 µmol/L of free emodin decreas-
ing to 21.8 µmol/L and 11.6 µmol/L of nontargeted TPGS 
liposomal emodin (100 nm), respectively (Table 4). Mean 
volume particle sizes of 100 nm and 50 nm had almost no 
influence on the IC50 of the nontargeted liposomes. Further, 
Tf–PEG3350–DSPE improved the cytotoxicity of TPGS 
liposomal emodin, with IC50 diminishing to 18.4 µmol/L 
and 9.6 µmol/L, respectively.
Mechanisms of emodin for leukemia
The Bcl-2 family of proteins are the best-characterized regula-
tors of apoptosis. Some members in this family, such as Bcl-2, 
Bcl-XL, and Mcl-1, suppress apoptosis, while Bax and Bcl-2 
homologous antagonist/killer promote apoptosis. Downregula-
tion of Bcl-2 and Mcl-1 and upregulation of Bax can potentially 
indicate the apoptosis of tumor cells. Mechanisms of emodin 
cytotoxicity based on the Bcl-2 family have also been inves-
tigated. Downregulated Bcl-2 along with unaffected Bax was 
found in human H460 non-small-cell lung cancer cell lines.2 
Upregulation of the Bax/Bcl-2 ratio was reported in human 
neuroblastoma cell lines SJ-N-KP 23 and human lung squamous 
carcinoma cell line CH27.22 Emodin decreased Mcl-1, but 
did not significantly affect the expressions of Bcl-2 and Bax 
proteins in myeloma cells, such as U266, IM-9, KMS-12-PE, 
RPMI8226,1 and HL-60,24 have also been reported.
To clarify whether the expressions of these cell-death-
related proteins are involved in emodin-induced apoptosis 
on K562 and MV4-11 leukemia cells, the Western blotting 
technique was utilized to test the level of proteins, such as 
Bcl-2, Bax, and Mcl-1.
Western blot images showed that when K562 cells were 
exposed to free emodin, the proteins were almost unchanged 
with emodin concentrations from 0 to 80 µmol/L (Figure 4A). 
However, in the TPGS liposomal emodin and Tf-targeted TPGS 
liposomal emodin groups, downregulation of Mcl-1 protein 
and upregulation of Bax protein were clearly observed with the 
concentrations as shown in Figure 4B and C.   Protein amounts 
were calculated using ImageJ software. In comparison with 
the control (empty vesicles), Bax protein was upregulated 
Table 3   IC50  of  L1210  cells  exposed  to  various  emodin 
formulations for 72 hours
Formulations IC50 (μmol/L)
TPgS liposomal emodin 13.2
mPEg2000–DSPE liposomal emodin 90.5
Free emodin 64.3
Empty TPgS liposomes 72.0
Abbreviations:  IC50,  half  maximal  inhibitory  concentration;  µmol,  micromole;   
L, liter; TPgS, D-α-tocopheryl polyethylene glycol 1000 succinate; mPEg2000–DSPE, 
methoxypolyethyleneglycol 2000-derivatized distearoyl-phosphatidylethanolamine.
Table 4   IC50  of  K562  and  MV4-11  cells  exposed  to  various 
emodin formulations for 72 hours
Formulations IC50 (μmol/L)
K562 MV4-11
Tf-targeted TPgS liposomal emodin (100 nm) 18.4 9.6
Nontargeted TPgS liposomal emodin (100 nm) 21.8 11.6
Nontargeted TPgS liposomal emodin (50 nm) 21.3 11.2
Free emodin 31.2 20.5
Abbreviations:  IC50,  half  maximal  inhibitory  concentration;  µmol,  micromole; 
L, liter; Tf, transferrin; TPgS, D-α-tocopheryl polyethylene glycol 1000 succinate; 
nm,  nanometer;  mPEg2000–DSPE,  methoxypolyethyleneglycol  2000-derivatized 
distearoyl-phosphatidylethanolamine.
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In addition, we have observed that the total amount of 
proteins decreased with increased concentration of   emodin 
formulations on K562 or MV4-11 cells for 72 hours. 
  Interestingly, the emodin concentrations at half the amount 
of total proteins assayed using bicinchoninic acid agreed with 
the corresponding IC50.
The above data suggest that emodin can induce the 
apoptosis of leukemia cells. TPGS liposomes enhance the 
cytotoxicity of emodin to K562 and MV4-11 cells by down-
regulation of Bcl-2 and Mcl-1 protein expressions, which is 
further improved by Tf-mediated active endocytosis.
Pharmacokinetics and biodistribution
To investigate the in vivo properties of TPGS liposomal emo-
din in comparison with mPEG2000–DSPE liposomal emodin 
and free emodin, pharmacokinetic and biodistribution studies 
were carried out in mice. Emodin formulations were admin-
istered by intravenous injection at a dose of 5 mg/kg.
Data, shown in Figure 6, indicated that when emodin 
was administered after intravenous bolus injection, the 
Figure 4 Western blot images of K562 cells exposed to various emodin formulations 
for 72 hours. (A) free emodin (0 refers to dimethyl sulfoxide); (B) TPgS liposomal 
emodin  (0  refers  to  empty  TPgS  liposomes);  (C)  Tf-targeted  TPgS  liposomal 
emodin (0 refers to empty Tf-targeted TPgS liposomes).
Abbreviations: Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; Mcl-1, 
myeloid cell leukemia 1; TPgS, D-α-tocopheryl polyethylene glycol 1000 succinate; 
Tf, transferrin.
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twofold by TPGS liposomes and about 3.5-fold by Tf-targeted 
TPGS liposomes when the emodin concentration was higher 
than 20 µmol/L. The Bcl-2 protein level of the K562 cells was 
0.7 times that of empty TPGS liposomes after exposure to 
80 µmol/L TPGS liposomal emodin for 72 hours. Of particular 
note, the nearly total downregulation of Bcl-2 was observed 
by Tf-targeted TPGS liposomal emodin above 20 µmol/L. 
Furthermore, Mcl-1 protein of K562 cells was almost totally 
downregulated by both Tf-targeted liposomal emodin and 
nontargeted liposomal emodin above 20 µmol/L. While in 
exposure to 80 µmol/L free emodin, Mcl-1 protein showed 
only 0.4 times that of the control (DMSO).
In contrast to K562 cells, Bax protein levels in MV4-11 cells 
were not influenced by emodin formulations (Figure 5). Bcl-2 
protein downregulation was obtained when emodin concen-
tration higher than 40 µmol/L in various formulations. It is 
worthy of note that almost total downregulation of Mcl-1 was 
also observed in the free emodin of 80 µmol/L (Figure 5A) 
and in the nontargeted liposomes and Tf-targeted liposomes 
of more than 40 µmol/L (Figure 5B and C).
Figure  5  Western  blot  images  of  MV4-11  cells  exposed  to  various  emodin 
formulations  for  72  hours.  (A)  Free  emodin  (0  refers  to  dimethyl  sulfoxide); 
(B) TPgS liposomal emodin (0 refers to empty TPgS liposomes); (C) Tf-targeted 
TPgS  liposomal  emodin  (0  refers  to  empty  Tf-targeted  TPgS  liposomes). 
Abbreviations: Bax, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma-2; Mcl-1, 
myeloid cell leukemia 1; TPgS, D-α-tocopheryl polyethylene glycol 1000 succinate; 
Tf, transferrin.
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concentrations of emodin in plasma quickly decreased. 
During the first 30 minutes postadministration of various 
formulations, both TPGS- and mPEG2000–DSPE-modified 
liposomes significantly improved the plasma concentrations 
of emodin and relatively prolonged the circulation time of 
emodin in comparison with free emodin. It is interesting 
that at 5 minutes postadministration, the plasma concen-
tration of mPEG2000–DSPE liposomes was significantly 
higher than that of TPGS liposomes, while at 15 minutes 
and 30 minutes, the opposite results were obtained. The area 
under the concentration–time curve (AUC) calculated using 
Phoenix WinNonlin 5.2 (Pharsight, St Louis, MO) showed 
that both TPGS and mPEG2000–DSPE liposomes promoted 
the retention of emodin in plasma, with AUC 1.7 times and 
1.9 times that of free emodin solution, respectively.
Biodistributions of various emodin formulations in the 
main organs such as the heart, liver, spleen, lung, and kidney 
are shown in Figure 7. It is noteworthy that both liposomes 
containing TPGS and mPEG2000–DSPE significantly 
elevated the emodin concentration in the heart in comparison 
with free emodin. Except at 15 minutes, significant differ-
ences for TPGS liposomal emodin and mPEG2000–DSPE 
liposomal emodin were observed (Figure 7A). Compared to 
free emodin, a 3.0-fold AUC for TPGS liposomal emodin 
and a 2.3-fold AUC for mPEG2000–DSPE liposomal emo-
din were also obtained (Table 5). It has been reported that 
emodin showed a specific effect for artery restenosis,8,9 and 
the nanoparticles could work as the carrier for restenosis.25 
Accumulation of emodin liposomes in the heart suggests that 
liposomes conjugating TPGS or mPEG2000–DSPE could be 
a potential carrier for emodin targeting against restenosis.
Data in Figure 7B showed that at 5 minutes postadmin-
istration of the various formulations, the mPEG2000–DSPE 
liposomes took much more emodin into the liver compared 
to TPGS liposomes or free emodin. However, the emodin 
concentrations decreased quickly. At 15 minutes, there was 
no significant difference between the TPGS liposomes and 
mPEG2000–DSPE liposomes, while at 30 minutes, the emo-
din concentration of TPGS liposomes was significantly higher 
than that of the mPEG2000–DSPE liposomes. Later, no signif-
icant differences were observed among the three   formulations. 
These data showed that emodin liposomes quickly distributed 
into the liver after the intravenous injection.
There were no significant differences between TPGS 
liposomal emodin and mPEG2000–DSPE liposomal emodin 
in the spleen (Figure 7C). It is surprising that free emodin 
showed similar concentration versus time profiles and AUCs 
to TPGS liposomal emodin and mPEG2000–DSPE lipo-
somal emodin in the liver and spleen. Emodin is a poorly 
water-soluble drug, which is dispersed in saline and further 
dissolved by adding NaOH solution to achieve a pH value 
of 10.0 for injection. Thus, we speculate that parts of the 
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Table 5 AUC values of emodin in various formulations (µg ⋅ min/mL, µg ⋅ min/g)
Formulations Plasma Heart Liver Spleen Lung Kidney
Free emodin 69.79 48.04 332.90 40.65 37.30 132.68
TPgS liposomal emodin 122.02 145.85 411.42 55.10 275.53 540.30
mPEg2000–DSPE liposomal emodin 133.74 109.40 435.85 50.16 81.06 278.20
Abbreviations: AUC, area under the emodin concentration versus time curve; µg, microgram; min, minute; mL, milliliter; g, gram; TPgS, D-α-tocopheryl polyethylene 
glycol 1000 succinate; mPEg2000–DSPE, methoxypolyethyleneglycol 2000-derivatized distearoyl-phosphatidylethanolamine.
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dissolved emodin in the alkaline solution may precipitate as 
drug nanocrystals after bolus injection into the blood vessels, 
and the nanocrystals are then taken into the liver and spleen 
by MPS phagocytosis. In addition, liposomes significantly 
enhanced emodin retention in the lung and kidney compared to 
free emodin (Figure 7D and E). TPGS liposomes also showed 
three times and two times greater AUCs than mPEG2000–
DSPE in the lung and kidney, respectively (Table 5). Emodin 
is a multifunctional drug extracted from the Chinese herbs. 
Antifibrosis in the liver,6,7 lungs5 and kidneys26 have been 
extensively studied. From the above biodistribution studies, 
the data suggest that TPGS liposomes could be a potential 
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delivery carrier of emodin for treating leukemia, artery rest-
enosis, and fibrosis in the liver, lungs, and kidneys.
Conclusion
In this study, a novel liposomal vesicle containing TPGS 
was formulated to entrap emodin, which showed a desirable 
EE, particle size, ultrastructural morphology, physical sta-
bility, in vitro release profile, and in vivo pharmacokinetics 
and biodistrubution in comparison with mPEG2000–DSPE 
liposomal emodin. In addition, TPGS liposomes enhanced 
the cytotoxicity of emodin to L1210, K562, and MV4-11 
leukemia cells more than mPEG2000–DSPE liposomal 
emodin, and Tf further promoted the antileukemia effect by 
regulation of Bcl-2 family membranes, such as Mcl-1, Bcl-2, 
and Bax. In conclusion, TPGS is a potential pegylated agent 
to compose liposomes for emodin.
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